Cancer in pathologically confirmed multiple system atrophy
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany..
PURPOSE: The aim of this study was to assess whether cancer occurs with increased frequency in multiple system atrophy (MSA). The pathological hallmark of MSA is glial cytoplasmic inclusions containing aggregated α-synuclein, and the related protein γ-synuclein correlates with invasive cancer. We investigated whether these two disorders are associated clinically.
METHODS: Medical records of 320 patients with pathologically confirmed MSA seen between 1998 and 2022 were reviewed. After excluding those with insufficient medical histories, the remaining 269 and an equal number of controls matched for age and sex were queried for personal and family histories of cancer recorded on standardized questionnaires and in clinical histories. Additionally, age-adjusted rates of breast cancer were compared with US population incidence data.
RESULTS: Of 269 cases in each group, 37 with MSA versus 45 of controls had a personal history of cancer. Reported cases of cancer in parents were 97 versus 104 and in siblings 31 versus 44 for MSA and controls, respectively. Of 134 female cases in each group, 14 MSA versus 10 controls had a personal history of breast cancer. The age-adjusted rate of breast cancer in MSA was 0.83%, as compared with 0.67% in controls and 2.0% in the US population. All comparisons were nonsignificant.
CONCLUSION: The evidence from this retrospective cohort found no significant clinical association of MSA with breast cancer or other cancers. These results do not exclude the possibility that knowledge about synuclein pathology at the molecular level in cancer may lead to future discoveries and potential therapeutic targets for MSA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Clinical autonomic research : official journal of the Clinical Autonomic Research Society - 33(2023), 4 vom: 13. Aug., Seite 451-458 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheshire, William P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alpha-Synuclein |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 03.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10286-023-00946-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356811190 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356811190 | ||
| 003 | DE-627 | ||
| 005 | 20231226071245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10286-023-00946-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356811190 | ||
| 035 | |a (NLM)37178348 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheshire, William P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer in pathologically confirmed multiple system atrophy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. | ||
| 520 | |a PURPOSE: The aim of this study was to assess whether cancer occurs with increased frequency in multiple system atrophy (MSA). The pathological hallmark of MSA is glial cytoplasmic inclusions containing aggregated α-synuclein, and the related protein γ-synuclein correlates with invasive cancer. We investigated whether these two disorders are associated clinically | ||
| 520 | |a METHODS: Medical records of 320 patients with pathologically confirmed MSA seen between 1998 and 2022 were reviewed. After excluding those with insufficient medical histories, the remaining 269 and an equal number of controls matched for age and sex were queried for personal and family histories of cancer recorded on standardized questionnaires and in clinical histories. Additionally, age-adjusted rates of breast cancer were compared with US population incidence data | ||
| 520 | |a RESULTS: Of 269 cases in each group, 37 with MSA versus 45 of controls had a personal history of cancer. Reported cases of cancer in parents were 97 versus 104 and in siblings 31 versus 44 for MSA and controls, respectively. Of 134 female cases in each group, 14 MSA versus 10 controls had a personal history of breast cancer. The age-adjusted rate of breast cancer in MSA was 0.83%, as compared with 0.67% in controls and 2.0% in the US population. All comparisons were nonsignificant | ||
| 520 | |a CONCLUSION: The evidence from this retrospective cohort found no significant clinical association of MSA with breast cancer or other cancers. These results do not exclude the possibility that knowledge about synuclein pathology at the molecular level in cancer may lead to future discoveries and potential therapeutic targets for MSA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alpha-synuclein | |
| 650 | 4 | |a Breast neoplasms | |
| 650 | 4 | |a Gamma-synuclein | |
| 650 | 4 | |a Multiple system atrophy | |
| 650 | 7 | |a alpha-Synuclein |2 NLM | |
| 700 | 1 | |a Koga, Shunsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Tipton, Philip W |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiya, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Owen A |e verfasserin |4 aut | |
| 700 | 1 | |a Uitti, Ryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Josephs, Keith A |e verfasserin |4 aut | |
| 700 | 1 | |a Dickson, Dennis W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical autonomic research : official journal of the Clinical Autonomic Research Society |d 1995 |g 33(2023), 4 vom: 13. Aug., Seite 451-458 |w (DE-627)NLM012644730 |x 1619-1560 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:4 |g day:13 |g month:08 |g pages:451-458 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10286-023-00946-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 4 |b 13 |c 08 |h 451-458 | ||